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Statins have proved to be very effective in reducing atherosclerotic cardiovascular 
disease (ASCVD) risk, with no apparent threshold at which low-density lipoprotein 
cholesterol (LDL-C) lowering is not associated with a reduced risk. Yet, several 
meta-analyses of statin trials show significant on-treatment residual risk of major 
cardiovascular (CV) events. This finding points to the unmet needs, in terms of 
LDL-C targets and ASCVD protection, of statin-treated patients, raising the ques-
tion of statin combination therapy. Ezetimibe is a cholesterol absorption inhibitor, 
with the potency to decrease LDL-C for about 10–18%, apolipoprotein B (apoB) for 
11–16%, while, in combination therapy with statins, leads to an additional LDL-C 
lowering of 25%, with a total LDL-C lowering of 34–61%. It is also estimated that 
10–20% of patients on statin treatment cannot tolerate them. As a result, adequate 
doses to achieve treatment target, or as recommended for the patient-specific risk 
profile, cannot be prescribed. Proprotein convertase subtilisin/kexin type 9 (PCSK9) 
Inhibitors are monoclonal antibodies that inhibit the binding of PCSK9 to LDL-C 
receptors. Besides a very potent lipid-lowering effect, PCSK9 inhibitors have added 
ASCVD risk reduction benefit due to a very aggressive LDL-C lowering action, 
especially beneficial in patients who are intolerant to statins.
Keywords: hyperlipidemia, statins, ezetimibe, PCSK9 inhibitors, cardiovascular 
diseases, cerebrovascular disease, prevention, adverse effects, diabetes, residual risk
1. Introduction
Atherosclerotic cardiovascular disease (ASCVD), including its clinical manifes-
tations, such as myocardial infarction (MI) and ischemic stroke (IS), is the leading 
morbidity and/or mortality cause worldwide. One of the most highly studied 
factors associated with ASCVD is low-density lipoprotein (LDL). Vast evidence has 
postulated that cholesterol-rich LDL and other apolipoprotein B (apoB)-containing 
lipoproteins (very low-density lipoproteins (VLDL), intermediate density lipopro-
teins (IDL), and lipoprotein(a) [Lp(a)]), are directly involved in the development 
of ASCVD [1].
Statins are the first-line anti-lipemic pharmacotherapy, having been shown to 
reduce both LDL-C levels and cardiovascular (CV) events. However, a considerable 
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number of statin-treated patients do not achieve target LDL-C levels, even after 
maximal statin dose-treatment, or are intolerant to intensive statin therapy [2].
In the aforementioned situations patients can largely benefit from an additional 
LDL-C lowering agent. Ezetimibe is a non-statin drug that can additionally reduce 
ASCVD risk, when added to a statin, leading to a total of 34–61% LDL-C reduction 
[3]. Proprotein Convertase Subtilisin-Like/Kexin Type 9 (PCSK9) inhibitors, one of 
the newest anti-lipemic agents, can lower LDL-C by 45–65%, and are also proven to 
have ASCVD risk reduction properties [4].
Therefore, the aim of this chapter is to address the question of therapeutic 
efficacy, as expressed through the lipid-lowering and anti-inflammatory effects, 
and atherosclerotic cardiovascular disease risk reduction when adding ezetimibe or 
PCSK9 inhibitors to statin therapy.
1.1 HMG-CoA reductase inhibitors—statins
3-Hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, 
commonly known as statins, have been one of the most frequently prescribed 
medications worldwide, since their introduction 30 years ago. Currently, there are 
six statin drugs available on the market—pitavastatin, atorvastatin, rosuvastatin, 
pravastatin, simvastatin and fluvastatin [5].
Statins are competitive, reversible inhibitors of HMG-CoA reductase, a rate-
limiting step in the process of cholesterol biosynthesis. HMG-CoA is a microsomal 
enzyme—reductase which catalyzes the conversion of HMG-CoA to l-mevalonate 
and coenzyme A. Inhibiting the HMG-CoA reductase, statins ultimately prevent the 
endogenous cholesterol production. Cholesterol concentration reduction triggers 
an up-regulation of the expression of low-density lipoprotein (LDL)-receptors in 
the hepatocytes, promoting uptake of LDL and LDL-precursors from the systemic 
circulation. Therefore, a significant part of the statins’ cholesterol-lowering action 
is a result of an indirect increase in LDL clearance from plasma. Additional mecha-
nisms of action include inhibition of the hepatic apolipoprotein B100 synthesis, and 
a reduction of the synthesis and secretion of triglyceride-rich lipoproteins [6].
Statins are composed of two parts, the pharmacophore, a dihydroxyheptanoic 
acid segment, and a moiety composed of a ring system with various substituents. 
According to the chemical modification of the ring system and the nature of its 
substituents, different statin structures are generated. Ring substituents define 
the solubility of the statins, along with many of their pharmacological proper-
ties. Among the statins, lovastatin, simvastatin, atorvastatin, and fluvastatin are 
lipophilic, whereas pravastatin and rosuvastatin are more hydrophilic. Different 
chemical structures lead to different pharmacokinetic properties, pharmacological 
effects and pleiotropic actions [7].
Statins can enter the systemic circulation passively, through the intestinal cells, 
and actively via the ATP-binding cassette (ABC) and solute carrier (SLC) transport-
ers. Two enzyme groups are involved in statin metabolism, the cytochrome P450 
(CYP450), and UDP-glucuronosyltransferase (UGT), mainly acting in the liver, 
and to a lesser extent, in the kidneys. Lipophilic statins are transported via passive 
diffusion, metabolized by the CYP450 enzymes, and mainly excreted through 
the biliary system. Hydrophilic statins enter the liver via active transport, and 
are actively excreted through the kidneys, mostly as unchanged drugs. Lipophilic 
statins have generally low bioavailability due to first pass metabolism. Absorption 
varies between 30 and 98%, and time to reach peak plasma concentration (Tmax) 
is within 4 h of administration. Statins are administrated orally as active hydroxy 
acids, except for lovastatin and simvastatin, which are administrated as lactone pro-
drugs, and then hydrolyzed to the hydroxy acid form. Their bioavailability varies; 
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pitavastatin has a bioavailability of 80%, whereas fluvastatin between 19 and 29%. 
The CYP3A4 isoenzyme is responsible for the metabolism of lovastatin, simvastatin 
and atorvastatin. Their active metabolites—2-hydroxy- and 4-hydroxy-atorvastatin 
acid from atorvastatin, and β-hydroxy simvastatin acid from simvastatin, carry a 
part of their inhibitory activity. Fluvastatin is mainly metabolized by the CYP2C9 
isoenzyme. Pravastatin is eliminated by both the kidney and liver, mostly as an 
unchanged drug [6–8].
1.2 Cholesterol absorption inhibitors—ezetimibe
Ezetimibe, a cholesterol absorption blocker, has been the focus of many tri-
als supporting its use in ASCVD risk reduction. For patients that cannot achieve 
target treatment goals with statin therapy alone, ezetimibe has proven to be a safe, 
well-tolerated medication which, combined with statins, leads to additional LDL-C 
reduction, thus resulting in a significant morbidity and/or mortality benefit [9].
Serum cholesterol is derived from two major sources: cholesterol synthesized  
de novo in the liver and cholesterol that has been absorbed from the gastrointestinal 
tract. Statins reduce serum cholesterol by reducing its biosynthesis in the liver. 
Ezetimibe, on the other hand, targets gastrointestinal cholesterol absorption. 
Ezetimibe acts at the brush boarder of the small intestine, by selectively inhibiting 
the cholesterol transport protein Niemann Pick C1 like 1 protein (NPC1L1), thus 
preventing uptake of intestinal luminal cholesterol micelles into the enterocytes. 
The reduced cholesterol uptake leads to hepatic LDL-C stores depletion, resulting in 
upregulation of hepatic LDL receptors, causing LDL-C clearance from the blood. It 
is also suggested that ezetimibe inhibits the hepatic NPC1L1 as well, thus leading to 
reduced hepatic cholesterol absorption [3, 10, 11].
Following ingestion, the drug is extensively (>80%) metabolized to its active 
form—ezetimibe-glucuronide. Glucuronidation of the 4-hydroxyphenyl group, 
by uridine 5′-diphosphate-glucuronosyltransferase isoenzymes, forms the major 
ezetimibe metabolite in the intestine and liver. Total ezetimibe (sum of ‘parent’ 
ezetimibe plus ezetimibe-glucuronide) concentrations reach a maximum 1–2 h after 
administration. Both the parent compound and the glucuronidated compound are 
absorbed, and recirculated via the hepatobiliary excretion, thus providing long-
term cholesterol absorption inhibition. This cycle accounts for the long half-life 
of ezetimibe—about 22 h, allowing for once-a-day dosing. About 10–15% of the 
drug is excreted in the urine, and the rest in the feces, mainly as the parent drug. 
Ezetimibe does not appear to be metabolized or interact with the cytochrome P450 
pathway, thus it does not affect bioavailability and kinetics of commonly used drugs 
that are affected by the CYP450 family [10, 12].
1.3 Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors
The discovery of PCSK9 in 2003 opened many new research directions in the 
cardiovascular field. Liver PCSK9 binds to the LDL receptor (LDL-R) and promotes 
its degradation in the endosomal/lysosomal pathway. Higher PCSK9 activity leads 
to lower liver LDL-R levels, resulting in reduced LDL-uptake from circulation, and 
thus in hypercholesterolemia [13].
This led to a conclusion that the inhibition of PCSK9 would mean that more 
LDL receptors would be recycled to the surface of the cell, thus increasing the 
clearance of LDL cholesterol from the circulation. Since then various approaches 
to the pharmacological inhibition of PCSK9 have been investigated, and parenteral 
anti-PCSK9 monoclonal antibodies (MoAbs) have been the most successful strategy 
to date. MoAbs are now in late-stage (phase 3 clinical trials) testing [14].
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Anti-PCSK9 MoAbs are known to bind at or near PCSK9’s binding site for the 
LDL-R. This sterically inhibits the interaction of PCSK9 with the LDL-R, thus 
reducing the degradation of the receptor. This markedly increases the clearance of 
LDL and substantially lowers plasma LDL cholesterol, as well as apolipoprotein-
B100 [15]. In 2015, the Food and Drug Administration (FDA) approved the PCSK9 
inhibitors alirocumab and evolocumab for patients with clinical atherosclerotic 
cardiovascular disease on maximally tolerated statin therapy who “require addi-
tional lowering of LDL-C” [16].
Evolocumab is a human monoclonal immunoglobulin G2 antibody directed 
against the circulating PCSK9 protein. Evolocumab is administered by subcutaneous 
injection to the abdomen, thigh, or upper arm. For patients with primary hyperlip-
idemia, who have clinical ASCVD, or heterozygous familial hypercholesterolemia, 
the recommended subcutaneous dose is 140 mg every 2 weeks or 420 mg once 
monthly. Maximum suppression of circulating unbound PCSK9 is seen after 4 h. 
Peak serum concentrations are obtained in 3–4 days, with an estimated bioavailabil-
ity of 72%. The drug is estimated to have an effective half-life of 11–17 days [17].
Alirocumab is a human monoclonal immunoglobulin G1 [IgG1] isotype antibody 
that binds to circulating PCSK9, thus inhibiting its action on LDL-R. Alirocumab 
reduces free PCSK9 in a concentration-dependent manner. Following a single 
subcutaneous administration of alirocumab 75 or 150 mg, maximal suppression 
of free PCSK9 occurs within 4–8 h. Within 4–8 weeks after initiating or titrating 
alirocumab therapy, LDL-C levels should be tested to determine the response and 
the need for (additional) dose adjustments. The drugs’ median apparent half-life 
at steady state is 17–20 days. Peak serum concentrations are obtained in 3–7 days, 
with an estimated bioavailability of 85%. At low concentrations, the elimination of 
alirocumab occurs predominately via saturable binding to PCSK9. At higher con-
centrations, elimination is through a nonsaturable proteolytic pathway [18].
2. Effects of statins
2.1 Effects of statin therapy on LDL-C concentrations
During the past 20 years, the extensive use of statin therapy among patients 
known to have an occlusive vascular disease, or are considered to be at increased 
risk of cardiovascular events, has been associated with descending actions on LDL 
and total cholesterol concentrations [19].
Different statins have different potencies, with the newer agents (e.g., atorv-
astatin and rosuvastatin) able to produce larger reductions in LDL cholesterol per 
mg of drug, compared to the older agents (e.g., simvastatin and pravastatin). Each 
dose doubling leads to an additional reduction of about 6 percentage points in LDL 
cholesterol (e.g., 43 vs. 49% reductions with atorvastatin 20 vs. 40 mg daily). The 
American College of Cardiology/American Heart Association (ACC/AHA) 2013 
Blood Cholesterol Guideline classified statin regimens as being of low intensity 
(e.g., <30% LDL-C reduction with simvastatin 10 mg daily), moderate intensity 
(e.g., 30% to <50% reduction with simvastatin 20–40 mg, atorvastatin 10–20 mg, 
or rosuvastatin 5–10 mg daily), or high intensity (e.g., ≥50% reduction with atorv-
astatin 40–80 mg or rosuvastatin 20–40 mg daily) [20].
High-intensity statin therapy would be expected to reduce LDL-C by at 
least 2 mmol/L in individuals with LDL-C concentrations of 4 mmol/L or 
more, but by only about 1 mmol/L in those presenting with concentrations of 
2 mmol/L. Consequently, since vascular events rates reductions, in patients treated 
with statins, are related to the absolute reductions in LDL-C, intensive statin 
5Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic…
DOI: http://dx.doi.org/10.5772/intechopen.82520
treatment should be used in individuals at higher risk of vascular events, rather 
than just on those with high cholesterol concentrations [21].
The Cholesterol Treatment Trialists’ (CTT) Collaboration was settled to conduct 
meta-analyses of randomized controlled statin-oriented trials involving at least 
2 years of treatment in at least 1000 patients. During the study treatment periods 
(on average 5 years), the average LDL-C reduction was about 1–1.5 mmol/L, 
comparing routine statin therapy vs. no routine statin therapy, with an additional 
LDL-C reduction of about 0.5 mmol/L in the trials comparing allocation to more vs. 
less intensive statin regimens. To summarize, an intensive statin regimen, compared 
to no statin therapy, reduced LDL-C concentrations by 1.5–2 mmol/L [22, 23].
2.2 Reductions in major vascular event (MVE) rates
Statins have been proven to be very effective in reducing ASCVD risk, with no 
apparent threshold at which LDL-C lowering is not associated with reduced risk. 
The Atherosclerosis Risk in Communities (ARIC) study, performed on 13,342 
individuals, provided evidence that protection against ASCVD happens in a graded 
fashion with LDL-C level [24]. The CTT meta-analyses detected about 25,000 
major vascular events (MVE) (composite of coronary deaths or non-fatal myocar-
dial infarctions, strokes of any type, and coronary revascularisation procedures). 
Comparing routine vs. no routine statin treatment, there was a 20% proportional 
reduction in the MVE rate per mmol/L LDL-C reduction. Regarding the comparison 
of more vs. less intensive statin regimens, the average 0.5 mmol/L further LDL-C 
reduction lead to an additional 15% proportional reduction in the MVE rate [22, 23].
By combining the findings from the two previously mentioned sets of trials, it 
can be concluded that a LDL-C concentration reduction by 2 mmol/L would reduce 
the MVE risk by about 45%. Given the aforementioned, larger LDL-C reductions 
should lead to larger risk reductions (e.g., 60–70% with 3–4 mmol/L LDL-C reduc-
tions); however, this is likely only to be clinically relevant in limited circumstances 
(such as for individuals with familial hypercholesterolemia who have very high 
LDL-C levels) [25].
High-intensity statin treatment (atorvastatin 80 mg) in the Treating to New 
Targets (TNT), the Incremental Decrease in Endpoints Through Aggressive Lipid 
Lowering (IDEAL) trial and Pravastatin or Atorvastatin Evaluation and Infection 
Therapy (PROVE-IT) trial, demonstrated an additional 11–23% relative risk reduc-
tion of major CVD events, when compared to moderate-intensity statin therapy 
(atorvastatin 10 mg, simvastatin 20–40 mg, or pravastatin 40 mg). Nonetheless, 
the atorvastatin 80 mg treated patients still experienced a major CVD event during 
the trials (ranging from 4 to 11% per year). Mean LDL-C levels in the atorvastatin 
80-mg groups ranged from 1.6 to 2.1 mmol/L [26–29].
The American College of Cardiology/American Heart Association 2013 Blood 
Cholesterol Guideline gives recommendations regarding statin therapy in terms of 
ASCVD prevention and risk reduction (Table 1) [20].
2.3 Reductions in coronary mortality
The CTT meta-analyses showed a 12% proportional reduction in vascular 
mortality per mmol/L LDL-C reduction, attributable to an approximately 20% 
proportional reduction in coronary deaths, 8% reduction in other cardiac deaths, 
and little effect on death due to all types of stroke combined. No matter the cause 
of coronary death, the risk reduction per mmol/L LDL-C reduction appear to be 
similar in patients with and without pre-existing vascular disease, and in those who 
present at different levels of baseline vascular risk [22, 23].
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Regarding the effect of different statins, and different statin treatment intensi-
ties, on coronary mortality, the TNT trial showed no significant differences in the 
risk of death from cardiovascular or noncardiovascular causes between the patients 
treated with 10 mg or 80 mg atorvastatin per day [27]. The IDEAL study compared 
the effects of high-intensity statin therapy (atorvastatin 80 mg/d) vs. low-intensity 
statin therapy (usual-dose simvastatin, 20 mg/d), on occurrence rates of a major 
coronary event, defined as coronary death, confirmed nonfatal acute MI, or cardiac 
arrest with resuscitation. The results failed to show a statistically significant differ-
ence in all-cause or cardiovascular mortality between the two treatment regimens 
[28]. The PROVE-IT trial aimed to compare the effects of 40 mg of pravastatin 
daily (standard therapy) vs. 80 mg of atorvastatin daily (intensive therapy) in 
patients hospitalized for acute coronary syndrome. The risk of death due to coro-
nary heart disease, myocardial infarction, or revascularization was reduced by 14% 
in the atorvastatin group, as compared with 22.3% in the pravastatin group [29].
2.4 The question of residual risk
Despite what was previously elaborated, a significant on-statin treatment residual 
risk of major CV events still exists. A meta-analysis of statin trials shows that there 
is residual CVD event risk even with LDL-C levels <2 mmol/L. The aforementioned 
TNT trial, conducted on patients with stable coronary artery disease (CAD), 
described an 8.7% incidence of a major event, over 5 years, in patients receiv-
ing 80 mg atorvastatin daily, with on-treatment LDL-C concentrations of 1.8–
2.6 mmol/L [24]. Findings like these point to the unmet needs of the patients treated 
with statins. Several cholesterol treatment guidelines recommend a LDL-C treatment 
goal of <2.6 mmol/L or < 1.8 mmol/L, depending on the level of risk. However, in the 
everyday clinical practise many high-risk patients fail to reach the goal [26].
The most resent Guidelines, the 2016 European Society of Cardiology and 
European Atherosclerosis Society (ESC/EAS) Guidelines for the management of 
Dyslipidemias and The 2017 Guidelines of the American Association of Clinical 
Endocrinologists (AACE) and the American College of Endocrinology (ACE) 
for Management of Dyslipidemia and Prevention of Cardiovascular Disease have 
recommended similar target LDL-C levels, and have suggested the use of combina-
tion therapy (ezetimibe and PCSK9 inhibitors) to achieve these targets in situations 
in which maximally tolerated statin monotherapy is insufficient (Table 2) [3, 26].
The AACE guidelines introduced an additional “extreme high-risk” category, 
which is not recognized by the ESC/EAS, and an additional treatment LDL-C target 
ASCVD Statin Benefit Groups [20]
Heart healthy lifestyle habits are the foundation of ASCVD prevention
Clinical ASCVD LDL-C ≥ 4.9 mmol/L Diabetes; age 40–75 
years1
Estimated 10-yr 
ASCVD risk ≥ 7.5%2; 
age 40–75 years1
• High-Intensity statin 
(age ≤ 75 years)
• Moderate-intensity statin if 
>75 years or not a candidate 
for high-intensity statin
• High-intensity statin
• Moderate-intensity statin 




• High-intensity statin 
if estimated 10 year 
ASCVD risk ≥ 7.5%
• Moderate- to high-
intensity statin
ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density lipoprotein-cholesterol. 
1With LDL-C of 1.8–4.9 mmol/L.
2Estimated using the Pooled Cohort Risk Assessment Equations.
Table 1. 
Statin therapy in ASCVD prevention and risk reduction according to the 2013 ACC/AHA blood cholesterol guideline.
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of <1.4 mmol/L. This “extreme high-risk” group represents patients with progres-
sive disease, despite LDL-C levels of <1.8 mmol/L while on-statin therapy. The 
rationale of the aforementioned approach is in the individualization of the total CV 
risk reduction, which can be better done if goals are predefined. Treatment goals 
are defined and tailored to the total CV risk level of each individual patient. The 
“individualized approach “may possibly result with better patient adherence to the 
therapy. The growing number of evidence suggests that LDL-C lowering beyond 
the guidelines-set goals may lead to further reduction of CVD events, which can be 
especially beneficial in patients at very high CV risk [3, 30].
Given what was previously discussed, in order to achieve this level of LDL-C 
reduction, combination therapy may be needed. The latest randomized clinical trials 
(RCTs), such as The LDL-C Assessment With Proprotein Convertase Subtilisin 
Kexin Type 9 Monoclonal Antibody Inhibition Combined With Statin Therapy 2 
(LAPLACE-2) trial, The FOURIER (Further Cardiovascular Outcomes Research 
With PCSK9 Inhibition in Subjects With Elevated Risk) trial, and The Reductions 
in Atherogenic Lipids and Major Cardiovascular Events: A Pooled Analysis of 10 
ODYSSEY Trials Comparing Alirocumab With Control, demonstrated that extremely 
low LDL-C levels (<0.5 mmol/L) appear to be safe. Furthermore, The IMPROVE-IT 
(Examining Outcomes in Subjects With Acute Coronary Syndrome: Vytorin vs. 
Simvastatin) and FOURIER trials demonstrated that not only such low levels are 
safe, but are also beneficial, in terms of additional CV risk reduction [30–34].
3. Combination therapy
3.1 Combination therapy: ezetimibe ad-on statin
The unmet needs in terms of LDL-C targets and ASCVD protection raised the 
question of statin combination therapy. It only needed to be right positioned. Such 
positioning was done in the 2016 ESC/EAS Guidelines for the management of 
Dyslipidemias (Table 3) [3], and also in The 2016 ACC expert consensus decision 
pathway on the role of non-statin therapies for LDL-cholesterol lowering in the 
management of atherosclerotic cardiovascular disease risk [35].
3.1.1 Effects of ezetimibe ad-on statins on LDL-C
The FDA-approved ezetimibe indications are for treatment of primary hyperlip-
idemia, alone or in combination with a statin; mixed hyperlipidemia in combination 
Risk profile of the patient Treatment target goal of LDL-C [3]
Very high CV risk <1.8 mmol/L, or at least 50% reduction if the baseline3 LDL-C is  
1.8–3.5 mmol/L (COR1 I/LOE2 B)
High CV risk <2.6 mmol/L, or at least 50% reduction if the baseline LDL-C is  
2.6–5.2 mmol/L (COR I/LOE B)
Low/moderate CV risk LDL-C goal of <3.0 mmol/L (COR IIa/LOE C)
CV, cardiovascular; LDL-C, low-density lipoprotein-cholesterol. 
1COR, class of recommendation.
2LOE, level of evidence.
3“Baseline LDL-C” refers to the LDL-C level in a subject not taking any lipid lowering medication.
Table 2. 




with fenofibrates; in homozygote familiar hyperlipidemia (HoFH) in combination 
with atorvastatin or simvastatin; and in homozygous sitosterolemia (phytosterol-
emia) [3, 26, 35].
In clinical studies, ezetimibe, as monotherapy, reduces LDL-C in hyper-choles-
terolemic patients by 15–22%. Combined therapy with statins provides an incre-
mental reduction in LDL-C levels of 15–20%, leading to a total LDL-C reduction by 
34–61%, as previously mentioned [3].
The most comprehensive data analysis for LDL-C lowering efficiency was per-
formed by the group of Descamps, published in 2015. 27 differently designed trials 
(double-blind placebo and/or active controlled studies), in which statins (type of 
statin, statin brand, potency or dose difference) were compared with ezetimibe ad-on 
statin, were included, with over 21,671 patients, analyzing variables such as variances 
(standard deviation [SD], coefficient of variation [CV], and root mean squared error 
[RMSE] adjusted for various factors) for % change from baseline in LDL-C. In this 
very comprehensive data analysis, ezetimibe ad-on statin was found to lead to signifi-
cantly more pronounced LDL-C lowering, as compared to statin monotherapy [36].
Data from a large retrospective observational study (more than 27,000 patients), 
published in 2014 by Toth, demonstrated a more pronounced LDL-C lowering 
effect of ezetimibe ad-on statin therapy, and a higher percentage of goal attainment 
(with respect to the risk profile of the patients), with one third of the patients not 
being able to attain the recommended LDL-C goal of <1.8 mmol/L. However, it was 
realized that there is a low prescription frequency of high-dose statins. Half of the 
patients (50.9%) remained on the same statin monotherapy, irrespective of their 
treatment goal achievement [37]. The significance of this study is even bigger given 
that it is a real life situation, and not a randomized study with strictly predefined 
inclusion criteria, study population etc.
The IMPROVE-IT study showed an on-trial average LDL-C level of 1.4 mmol/L 
in the simvastatin-ezetimibe group, as compared to 1.8 mmol/L in the simvastatin-
monotherapy group (p < 0.001), leading to a total amount of LDL-C reduction 
of about 24% [38]. There are also a lot of small-scale studies that demonstrate 
Clinical setting COR1
LOE2
Treatment target goal of LDL-C COR1
LOE2
Hypercholesterolemia
If the goal is not reached with statins, ad-on ezetimibe




Intense-dose statin, often in combination with 
ezetimibe
I/C <2.6 mmol/L, or
<1.8 mmol/L in presence of CVD
IIa/C
ASC
If the goal is not reached with the highest tolerable 
statin dose, ad-on ezetimibe in post-ACS patients
IIa/B <1.8 mmol/L, or
a reduction of at least 50% if the 
baseline3 LDL-C is 1.8–3.5 mmol/L
CKD stages 3–5
are high or very high CV risk patients
The use of statins or ezetimibe ad-on statin is indicated 
in non-dialysis dependent patients
I/A Depends of the risk profile of the 
individual patient
I/A
ACS, acute coronary syndrome; FH, familial hypercholesterolemia; CKD, chronic kidney disease; LDL-C,  
low-density lipoprotein-cholesterol. 
1COR, class of recommendation.
2LOE, level of evidence.
3“baseline LDL-C” refers to the level in a subject not taking any lipid lowering medication.
Table 3. 
Recommendations for ezetimibe add-on statin combination therapy according to the 2016 ESC/EAS guidelines 
for the management of dyslipidemias.
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superiority of ezetimibe ad-on statin therapy in terms of LDL-C lowering. For 
example, the Japanese study by Uemura, performed on 39 patients, compared two 
regimens: 10 mg atorvastatin + 10 mg ezetimibe vs. 20 mg atorvastatin in high risk 
patients with CAD and type 2 diabetes (T2DM). A significant improvement of the 
lipid profile was found in both groups in terms of total, LDL-C and high-density 
lipoprotein cholesterol (HDL-C), with a more pronounced improvement in the 
ezetimibe ad-on atorvastatin group (p = 0.005). A significant effect on the Apo 
B/Apo A-I ratio and remnant-like particle cholesterol was observed only in the 
atorvastatin ad-on ezetimibe treatment group. Probably the finding that gives as 
the most powerful information is the effect on oxidized LDL-C [malondialdehyde-
modified LDL (MDA-LDL)], a form that is responsible for the proaterogenic 
effects of LDL-C, that was significantly more pronounced with the atorvastatin 
ad-on ezetimibe treatment (p = 0.0006) [39]. The existence of pleotropic effects, 
other than the hypo-lipemic effect that is widely recognized for statins, is eviden-
tially true for ezetimibe as well. Evidence of anti-inflammatory and anti-oxidative 
effects is cumulating. Another Japanese study, by Tobaru, was performed on 35 
CAD patients pre-treated with statins who remained above targeted LDL-C level. 
In terms of hypo-lipemic effect, significant additional decrease of total C, LDL-
C, remnant lipoprotein C, LDL/HDL-C ratio was observed, and the percentage 
of patients who achieved target LDL-C level increased to 65.4% (p = 0.001) in 
the ezetimibe ad-on statin group. Although no significant effect was achieved on 
high-sensitive C-reactive protein (hsCRP) and oxidative stress markers, a sig-
nificant reduction of tumor necrosis factor-α (TNF-α), 1.36 vs. 0.96 (p = 0.042) 
was observed [40]. On the other hand, given the IMPROVE-IT trial in which two 
laboratory targets were set: LDL-C (<1.8 mmol/L) and hsCRP (<2 mg/L), Bohula 
and colleagues summarized that ezetimibe ad-on statin treatment was far more 
successful in achieving both targets, or it was concluded: “Significantly more 
patients treated with ezetimibe/simvastatin met prespecified dual LDL-C and 
hsCRP targets, than patients treated with simvastatin alone (50% vs. 29%, p < 
0.001)”. Reaching both LDL-C and hsCRP targets was associated with improved 
outcomes after multivariable adjustment (38.9% vs. 28.0%, adjusted hazard ratio, 
0.73, 0.66–0.81; p < 0.001) [38].
3.1.2 Effects of ezetimibe ad-on statins on ASCVD outcome
The potential benefits of adding an additional lipid lowering agent—ezetimibe 
on statin therapy for CVD prevention and risk reduction have been confirmed in 
several clinical trials.
The impact of dual lipid-lowering strategy with ezetimibe and atorvastatin on 
coronary plaque regression in patients with percutaneous coronary intervention: 
The Multicenter Randomized Controlled PRECISE-IVUS trial evaluated the effects 
of ezetimibe ad-on atorvastatin vs. atorvastatin monotherapy on the lipid profile 
and coronary atherosclerosis in Japanese patients who underwent percutaneous 
coronary intervention (PCI). The combination therapy resulted in lower levels 
of LDL-C, compared to atorvastatin monotherapy (1.6 mmol/L vs. 1.9 mmol/L; 
p < 0.001), and in the same time coronary plaque regression was observed in sig-
nificantly higher percentage of patients who received atorvastatin ad-on ezetimibe 
(78% vs. 58%; p = 0.004) [41].
The majority of studies addressing the efficacy of ezetimibe ad-on statin 
treatment are with simvastatin, including the Simvastatin and Ezetimibe in 
Aortic Stenosis (SEAS) study, in patients with aortic stenosis, and the Study of 
Heart and Renal Protection (SHARP) (Simvastatin plus ezetimibe) trial, includ-
ing 23% high risk patients with diabetes and chronic kidney disease (CKD) with 
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or without requiring dialysis. The combination therapy demonstrated superiority 
over statin monotherapy in LDL-C reduction, translated in reduced primary end-
point of first major ASCVD event: nonfatal MI or CV death, non-hemorrhagic 
stroke, or any arterial revascularization procedure, over a median follow up of 
4.9 years [3, 42].
The landmark trial on ezetimibe-statin combination therapy, the largest and 
the longest one with ezetimibe, is the Improved Reduction of Outcomes: Vytorin 
Efficacy International Trial (IMPROVE-IT). A total of 18,144 patients with acute 
coronary syndrome (ACS) were randomized to ezetimibe (10 mg) or placebo, all 
receiving 40 mg simvastatin, which was increased to 80 mg if LDL-C on treatment 
was >2.04 mmol/L. The event rates for the primary end point at 7 years were 32.7% 
in the simvastatin-ezetimibe group and 34.7% in the simvastatin-monotherapy 
group, with an absolute risk reduction of 2% (HR 0.936; 95% CI 0.89–0.99; 
p = 0.016). Ischemic stroke was reduced by 21% (p < 0.008). Nevertheless, no ben-
efit in reducing all-cause mortality or deaths from CV causes was observed, which 
was not unexpected, as prior trials of intensive vs. standard-dose statin therapy 
did not demonstrate a benefit in terms of mortality as well. There was no evidence 
of harm caused by the further LDL-C reduction. In this group of patients, already 
treated with statins to reach the goal, the absolute benefit from the added ezetimibe 
was small, although significant. However, the study supports the proposition that 
LDL-C lowering by means other than statins is beneficial and can be performed 
without adverse effects [38].
The diabetic sub-group analysis in the IMPROVE-IT trial provided the outcomes 
in 4933 (27%) patients with diabetes, one of the pre-specified trial subgroups. 
In this patient subset, ezetimibe ad-on statin decreased LDL-C at 1 year by 
1.1 mmol/L, as compared to 0.6 mmol/L with statin monotherapy. Diabetic patients 
on ezetimibe ad-on statin therapy had a 14% relative risk reduction, or 5.5% 
absolute reduction, compared with a 2% absolute risk reduction for non-diabetics. 
The most notorious reductions were seen regarding ischemic stroke (39%), MI 
(24%), and the composite of death due to CV causes, MI or stroke (20%). These 
CV effects of ezetimibe ad-on statin therapy are considered to be a result of the 
more prominent reduction of LDL-C (mean 0.5 mmol/L), compared to simvastatin 
monotherapy, with an average value of 1.4 mmol/L. This sub-study analysis demon-
strated superiority of the statin-ezetimibe combination therapy in CV prevention in 
diabetic subsets especially [26, 34, 35, 38].
Another significant effect of ezetimibe ad-on statin therapy is cerebrovascular 
protection. The 2013 ACC/AHA cholesterol guideline recommends the use of 
ezetimibe as an ad-on statin, additional LDL-C lowering agent in stroke patients 
[35]. The advantage of ezetimibe ad-on statin therapy in this patient subgroup 
was observed in the IMPROVE-IT study. The highest risk benefit was observed 
in the subgroup of patients with ischemic CVD with a 21% relative reduction of 
ischemic stroke (p < 0.008). The addition of ezetimibe as a non-statin type drug, to 
statin treatment contributed to further reduction of LDL-C, which translated into 
additional decrease in reoccurrence and mortality of/from cerebrovascular events. 
Achieving target values with ezetimibe ad-on statin combination allows administra-
tion of low to moderate-dose statin, which decreases the risks of adverse effects 
related to high-dose statin therapy [43].
The current trial results make it obvious that the higher the risk profile of the 
patient is, the bigger is the benefit, in terms of risk reduction, when ezetimibe 
is ad-on statin treatment. Taken together, all these studies support the decision 
to propose ezetimibe as a second-line therapy, in association with statins, when 
the therapeutic goal is not achieved with the maximal tolerated statin dose or in 
patients intolerant or with contraindications to these drugs [3, 35].
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3.2 Combination therapy: PCSK9 inhibitors ad-on statin
3.2.1 Key points
• The FDA approved the first PCSK9 inhibitor in 2015
• There are currently two PCSK9 inhibitors on the market, alirocumab and 
evolocumab
• There was a third PCSK9 inhibitor—bococizumab, but its’ development was 
discontinued by Pfizer in late 2016. The key reasons for this were a high level 
of immunogenicity and wide variability in the LDL-C lowering response. 
Immunogenicity: in statin-treated patients, PCSK9 inhibition with bococizumab 
led to a short-term LDL-C reduction of 55–60%. However, this effect was 
attenuated over time in 10–15% of patients due to the development of anti-
drug antibodies. This effect was specific to bococizumab, which is a partially 
humanized monoclonal antibody, characterized by substitution of rodent 
deoxyribonucleic acid (DNA) sequences for <5% of human DNA sequences. It 
is thought that this substitution may have directly affected the immunogenic-
ity of the antibody. This effect has not been reported for either evolocumab 
or alirocumab, which are fully human monoclonal antibodies. This immuno-
genicity may also explain the higher rate of injection site reactions (~10%) 
observed with bococizumab, compared with either alirocumab or evolocumab 
(<5%). Variability in LDL-C lowering response: Irrespective of the presence or 
absence of antidrug antibodies, there was wide individual variability in the 
LDL-C lowering response with bococizumab; about 1 in 10 showed no reduc-
tion in LDL-C levels
• Patients with familial hyperlipidemia and those with clinical ASCVD, not 
reaching lipid-reducing goals, including those with statin intolerance, are at 
greatest need of PCSK9 inhibitors, because no adequate alternative treat-
ment exists
• Multiple guidelines with different approaches to lipid treatment have created 
confusion among clinicians; thus, defining the patients with ASCVD, or at 
high CV risk, who have not met LDL-C treatment goals is complicated
• Although PCSK9 inhibitors seem to support the LDL-C hypothesis (the lower 
the LDL-C level, the lower the CV risk), results of ongoing long-term outcome 
studies are yet to be presented
• Prescribing PCSK9 inhibitors will likely be limited by economics rather than 
by clinicians’ judgment about the best interest of their patients [44].
Many believe that proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibi-
tors are the pharmacotherapeutic innovation of the past 2 decades in terms of CV 
events prevention.
The 2017 Update of ESC/EAS Task Force on practical clinical guidance for pro-
protein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic 
cardiovascular disease or in familial hypercholesterolemia defined:
Patients with clinical ASCVD and substantially elevated LDL-C levels (patients 
already on maximally tolerated statin therapy (ideally with concomitant  
ezetimibe), or unable to tolerate three or more statins), and,
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Familial hypercholesterolemia (FH) patients without clinical ASCVD but with 
substantially elevated LDL-C levels (patients on maximally tolerated statin therapy 
plus ezetimibe), as priority patient groups for PCSK9 inhibitors (Figure 1) [45].
3.2.2 LDL-C lowering and PCSK9 inhibitors: what have we learned?
The Further Cardiovascular Outcomes Research With PCSK9 Inhibition in 
Subjects With Elevated Risk (FOURIER) trial, aimed to evaluate the efficacy of evo-
locumab, compared to placebo, in patients with clinically evident CVD. 69% of the 
patients were on a high-intensity statin, while 30% were on a moderate-intensity 
statin therapy, randomized to evolocumab 140 mg subcutaneous every 2 weeks or 
420 mg monthly (n = 13,784) vs. placebo every 2 weeks (n = 13,780). Evolocumab 
led to a 59% LDL-C level reduction (from 2.4 mmol/L to 0.78 mmol/ L), with an 
absolute LDL-C reduction of 1.4 mmol/L [46].
The Goal Achievement After Utilizing an Anti-PCSK9 Antibody in Statin 
Intolerant Subjects-3 (GAUSS-3) trial aimed to evaluate the effect of 24 weeks 
Figure 1. 
Appropriate use of PCSK9 inhibitor, as recommended in 2017 update of ESC/ESC task force on practical clinical 
guidance for proprotein convertase subtilisin/kexin type 9 inhibition in patients with atherosclerotic cardiovascular 
disease or in familial hypercholesterolemia. ASCVD, atherosclerotic cardiovascular disease; LDL-C, low-density 
lipoprotein-cholesterol; 1Including: familial hypercholesterolemia; diabetes mellitus with target organ damage, or 
a major risk factor; severe and/or extensive ASCVD; rapid progression of ASCVD (i.e. repeated ACS, unplanned 
coronary revascularizations). 2Including: diabetes mellitus with target organ damage, or a major risk factor; 
Lipoprotein(a) > 50 mg/dL; major risk factors: smoking, marked hypertension; >40 years of age without treatment; 
premature ASCVD (<55 years in males and <60 years in females) in first-degree relatives; imaging indicators.
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of evolocumab administered subcutaneously (SC) every month, compared with 
ezetimibe, on LDL-C levels in adults with high cholesterol, who are unable to 
tolerate an effective dose of a statin due to muscle-related side effects (MRSE). 
Evolocumab produced significantly larger reductions in LDL-C levels, compared 
to ezetimibe (16.7% reduction with ezetimibe and a more than 50% reduction 
with evolocumab). Despite very high baseline values, the LDL-C goal of less than 
1.8 mmol/L was achieved in nearly 30% of evolocumab-treated patients and 1.4% 
of ezetimibe-treated patients. The LDL-C reduction for both drugs was stable for 
4 weeks and sustained during the course of the 24 weeks of treatment [47].
The effect of evolocumab or ezetimibe added to moderate- or high-intensity statin 
therapy on LDL-C lowering in patients with hypercholesterolemia—the LAPLACE-2 
randomized clinical trial evaluated the efficacy and tolerability of evolocumab 
when used in combination with a moderate- vs. high-intensity statin. 2067 patients 
with primary hypercholesterolemia and mixed dyslipidemia were randomized to 24 
treatment groups. Patients were initially randomized to a daily, moderate-intensity 
(atorvastatin 10 mg, simvastatin 40 mg, or rosuvastatin 5 mg) or high-intensity 
(atorvastatin 80 mg, or rosuvastatin 40 mg) statin. After a 4-week lipid-stabilization 
period, patients were randomized to compare evolocumab (140 mg every 2 weeks) 
vs. placebo (every 2 weeks) or ezetimibe (10 mg daily; atorvastatin patients only) 
when added to statin therapies. In patients treated with atorvastatin (10 mg or 
80 mg), the addition of ezetimibe resulted in LDL-C reductions by 17–24% from 
baseline, compared with the addition of evolocumab, administered every 2 weeks, 
which reduced LDL-C values by 61–62% (treatment differences vs. placebo and 
ezetimibe both significant [p < 0 .001]. For patients receiving a moderate-intensity 
statin, evolocumab reduced LDL-C values from a baseline mean of 3.1 mmol/L to 
an on-treatment mean of 1.2 mmol/L, and 88–94% of the patients achieved target 
LDL-C levels, less than 1.8 mmol/L. For patients receiving a high-intensity statin, 
evolocumab reduced LDL-C values from a baseline mean of 2.4 mmol/L to an on-
treatment mean of 0.9 mmol/L, and 94% achieved the target LDL-C value. In the 
atorvastatin-treated patients, addition of ezetimibe resulted in achievement of an 
LDL-C level less than 1.8 mmol/L in 17–20% of patients receiving moderate-intensity 
statins and 51–62% of those receiving high-intensity statins, vs. 86–94% of patients 
achieving target LDL-C values in the evolocumab-atorvastatin group [31].
The efficacy and safety of alirocumab in high cardiovascular risk patients with 
inadequately controlled hypercholesterolemia on maximally tolerated doses of 
statins: the ODYSSEY COMBO II randomized controlled trial aimed to compare 
efficacy, in terms of LDL-C lowering, and safety of alirocumab vs. ezetimibe as 
ad-on therapy to maximally tolerated statin treatment in high CV risk patients with 
inadequately controlled hypercholesterolemia. Patients were randomized to subcu-
taneous alirocumab 75 mg every 2 weeks (plus oral placebo) or oral ezetimibe 10 mg 
daily (plus subcutaneous placebo) on a background of statin therapy. At week 24, 
mean ± SE reductions in LDL-C from baseline were 50.6 ± 1.4% for alirocumab 
vs. 20.7 ± 1.9% for ezetimibe (p < 0.0001). 77.0% of alirocumab and 45.6% of 
ezetimibe patients achieved target LDL-C values of <1.8 mmol/L (p < 0.0001). 
Mean achieved LDL-C levels, by week 24, were 1.3 mmol/L with alirocumab and 
2.1 mmol/L with ezetimibe [32].
3.2.3 Cardiovascular outcome studies with PCSK9 inhibitors: what have we learned?
The FOURIER trial, evaluating the effect of evolocumab on the risk of CV death, 
MI, stroke, hospitalization for unstable angina, or coronary revascularization, in 
27,564 patients with clinically evident CVD, is the first randomized study to be 
completed, regarding PCSK9 inhibitors long-term efficacy and safety. The primary 
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outcome, incidence of CV death, MI, stroke, hospitalization for unstable angina, or 
coronary revascularization, occurred in 12.6% of the evolocumab group vs. 14.6% 
of the placebo group (p < 0.0001). There was a 9.8% absolute MACE rate reduction, 
compared to 11.3% with placebo, over 2.2 years, with a relative risk reduction of 
15%. This finding was consistent among all tested subgroups. Benefit was enhanced 
among higher-risk subgroups (those with recent MI, multiple prior MIs, and residual 
multivessel coronary artery disease), compared to those without such characteris-
tics. There was a linear relationship between LDL-C and adverse CV events, such 
that adverse events continued to decline to the lowest levels of LDL-C (p = 0.0012). 
Among those with baseline LDL-C < 1.8 mmol/L, evolocumab reduced the primary 
endpoint (hazard ratio [HR] 0.80, 95% confidence interval [CI] 0.60–1.07) to a 
similar degree as those with baseline LDL-C ≥ 1.8 mmol/L  
(HR 0.86, 95% CI 0.79–0.92; p = 0.65 for interaction).
There was a greater absolute reduction in major adverse events for evolocumab vs. 
placebo among those with the highest baseline inflammatory risk (among those with 
high-sensitivity C-reactive protein <1 mg/dl, 1–3 mg/dl, and >3 mg/dl, there was 
an absolute reduction in the primary outcome of 1.6, 1.8, and 2.7%, respectively). 
PCSK9 inhibition represents a novel approach to lower LDL-C levels and improves 
cardiovascular outcomes. However, for the duration of follow-up, there was no 
benefit on cardiovascular or all-cause mortality, and cost remains an issue [46].
Regarding alirocumab, cardiovascular outcomes and safety will be assessed in an 
ongoing study, the ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes 
After an Acute Coronary Syndrome During Treatment With Alirocumab trial. 
18,600 patients, who have experienced an acute coronary syndrome (ACS), are 
allocated to alirocumab or placebo, for a maximum duration of 64 months. The 
primary objective of the trial is to compare the effect of alirocumab with placebo 
on the occurrence of cardiovascular events (composite endpoint of coronary heart 
disease (CHD) death, non-fatal MI, fatal and non-fatal IS, unstable angina requir-
ing hospitalization). No results are reported yet [32].
4. Safety profiles of statin monotherapy and statin combination therapy
4.1 Adverse effects of statin therapy
The only excesses of adverse events that have been reliably demonstrated to be 
caused by statin therapy are myopathy and diabetes mellitus, along with a probable 
excess of hemorrhagic stroke. However, the absolute risks of these adverse effects 
remain small, by comparison with the absolute benefits [25].
4.1.1 Increases in myopathy rates
Approved statin regimens have been associated, both in observational studies 
and in randomized trials, with large relative risks for myopathy, but typically with 
small absolute excesses (about 1 case per 10,000 people treated per year), and even 
smaller excesses in the incidence of rhabdomyolysis (about 2–3 cases per 100,000 
treated per year). It usually resolves rapidly when statin therapy is . [48]. The risk 
of myopathy is dose related and it appears to depend on the statin circulation levels. 
In the Study of the Effectiveness of Additional Reductions in Cholesterol and 
Homocysteine (SEARCH) randomized trial, simvastatin 80 mg daily produced a 
more than ten-fold higher rate (at least 1 case of myopathy per 1000 patients treated 
yearly), compared to 20 mg daily (about 1 case per 10,000 yearly), so the high-dose 
regimen is no longer recommended routinely [49].
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4.1.2 Increases in diabetes rates
In the Justification for the Use of Statins in Primary Prevention: An Intervention 
Trial Evaluating Rosuvastatin (JUPITER) randomized trial, among 17,802 patients 
without a history of vascular disease, concentrations of glycated hemoglobin, after 
2 years, were slightly higher among the patients allocated to rosuvastatin 20 mg 
daily compared to those allocated to placebo (5.9 vs. 5.8%; p = 0.001). There was 
also a small excess of newly diagnosed diabetes (3.0 vs. 2.4%; p = 0.01), which 
corresponds to a 25% proportional increase. In subsequent meta-analyses, standard 
statin dose regimens were associated with a proportional increase of about 10% in 
reported diabetes, and more intensive statin regimens (as used in JUPITER) with 
about a 10% further increase. This excess of diabetes diagnoses appeared soon after 
the start of statin therapy, mainly among patients who had previous risk factors for 
diabetes [50].
4.1.3 Probable increases in hemorrhagic stroke rates
In The Stroke Prevention by Aggressive Reduction of Cholesterol Levels 
(SPARCL) trial, among 4731 patients with prior cerebrovascular disease, allocation 
to atorvastatin 80 mg daily produced a definite reduction in ischemic stroke (218 
[9.2%] vs. 274 [11.6%]; p = 0.008), but there was also a possible increase in hemor-
rhagic stroke (55 [2.3%] vs. 33 [1.4%]; p = 0.02). When these results were combined 
with those from the other trials included in the CTT meta-analysis, there was a 
21% (95% CI 5–41; p = 0.01) proportional increase in the incidence of hemorrhagic 
stroke per mmol/L reduction in LDL-C [51].
4.2 Safety profile of ezetimibe ad-on statins combination therapy
The relationship between lipid-lowering medications, glycemic control, insulin 
resistance and new-onset diabetes has been studied since the introduction of 
hipo-lipemic medications. We know that glycemic control is impaired not only by 
statin treatment but also with niacin. At the opposite, bile-acid sequestrates dem-
onstrate moderate lipid and glucose lowering effects, and fibrates (particularly 
bezafibrate) may produce beneficial effects on glucose metabolism and insulin 
sensitivity. Considering statins, as the most widely used hypo-lipemic drugs, 
this is an important issue. Statins lead to a mild elevation of hemoglobin A1c 
(HgbA1c) and fasting plasma glycose (FPG), and increase the incidence of new-
onset diabetes, an effect known to be dose and agent dependent (Pravastatin and 
Pitavastatin have less diabetogenic effect and positive impact on insulin sensitiv-
ity). The aforementioned is most pronounced in patients with baseline impaired 
fasting blood glucose (FBG), at older age and with metabolic syndrome. However, 
it has been demonstrated that the risk of new-onset diabetes is overweight by the 
benefit of CV risk reduction [3].
For a long period of time there was a lack of clinical trials addressing the 
same question in ezetimibe treatment, but data was gathered from experimental 
animal studies that described how ezetimibe ameliorates metabolic markers, such 
as hepatic steatosis and insulin resistance. The process is via inhibition of the 
intestinal cholesterol absorption, and inhibition of the hepatic NPC1L1, leading to 
decreased hepatic insulin resistance, improved glycemic control and insulin sensi-
tivity, especially in patients with metabolic disorders (obesity and hepatic ste-
atosis). This was harder to prove in humans, as ezetimibe is usually used as statin 
co-therapy and individual impact of ezetimibe cannot be evaluated. In a recently 
published systematic review of randomized clinical trials, performed by Wu 
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and co-authors on 2440 patients, experimental data was confirmed. Ezetimibe 
did not cause any adverse effects in terms of increased levels of FBG and HbA1c. 
Compared with high-dose statin therapy, ezetimibe ad-on low-dose statin for 
more than 3 months may even have beneficial effects on glycemic control [52].
Statin associated muscle symptoms are a very common side effect, also known 
to be dose-dependent. It seems that ezetimibe ad-on low dose statin therapy is one 
of the possibilities to achieve good LDL-C control and CV risk reduction with lesser 
side effects, as demonstrated with myalgia [53]. The 2016 ESC/EAS Guidelines for 
the management of dyslipidemias recommend ezetimibe to be considered in com-
bination with a low-dose statin or second- or third-line statin in order to manage 
statin-attributed muscle symptoms [3].
4.3 Safety profile of PCSK9 inhibitors ad-on statins combination therapy
Despite this new evidence from the FOURIER trial, gaps remain in our knowl-
edge regarding the use of PCSK9 inhibition in clinical practice. The ODYSSEY 
Outcomes trial will provide additional information in patients treated with a PCSK9 
inhibitor within 1–12 months [45].
As with all novel treatments, long-term safety remains to be established. To 
date there are exposure data for up to 4 years’ treatment with a PCSK9 inhibitor, 
involving a background of concomitant statin therapy. Potential injection site 
reactions occurred in <5% of patients, and were mainly of very mild intensity with 
no evidence of a cumulative effect. When the PCSK9 inhibitor was compared to the 
previous standard of care (statin with or without ezetimibe), annualized event rates 
for muscle symptoms (4.7% vs. 8.5% with standard of care), and new-onset diabe-
tes (2.8% vs. 4.0%, respectively) appeared similar [45].
The safety of very low LDL-C levels merits special consideration, given that one 
in four patients treated with evolocumab in FOURIER attained LDL-C levels less 
than 0.5 mmol/L. Evidence to date suggests no detrimental impact on steroid hor-
mone production, enterohepatic circulation of bile acids, or neuronal cell function. 
Indeed, these LDL-C levels are also consistent with the very low levels observed in 
newborns which, despite the physiological and developmental demands of infancy, 
are compatible with normal development [54].
Additionally, data from the ODYSSEY program, the FOURIER and 6-year 
follow-up from the IMPROVE-IT trial showed no increase in adverse events includ-
ing severe muscle symptoms, liver enzyme elevation, cognitive adverse events, or 
hemorrhagic stroke with very low LDL-C levels [45].
5. The war of today
We now know the battle is going to be very hard. The “old ones” are not ready to 
go to history, while the “young ones” are still to be proven. What does the newest 
published data say? In January 2018 Khan and co-authors published a meta-analysis 
of statins, PCSK9 inhibitors and ezetimibe, the later two with or without statins, 
regarding ASCVD reduction benefit. The most comprehensive meta-analysis 
included 189,116 patients from 39 randomized control trials. PCSK9 inhibitors were 
ranked as the best treatment for prevention of major adverse cardiovascular events: 
myocardial infarction and stroke. Statins were ranked as the most effective therapy 
for reducing all-cause and CV mortality. In terms of reduction of CV mortality 
PCSK9 inhibitors were ranked as the second best treatment followed by ezetimibe 
ad-on statin [55].
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6. Conclusion
Statins remain the cornerstone anti-lipemic treatment, proven to be very effec-
tive in reducing ASCVD risk. Ezetimibe ad-on statin combination therapy is an 
effective treatment that leads to additional LDL-C lowering, recommended in situ-
ations where with maximal or maximally tolerated statin monotherapy treatment 
LDL-C target goals cannot be achieved. It leads to an additional CVD risk reduction, 
and in the same time is safe, with a possible beneficial effect over the statin adverse 
influence on glycemic metabolism. Having in mind the evidence from the first 
of the cardiovascular outcomes studies with PCSK9 inhibitors, the addition of a 
PCSK9 inhibitor should be considered in patients with ASCVD, and in FH patients 
without a prior clinical event, who have substantially elevated LDL-C levels despite 
maximally tolerated statin with or without ezetimibe therapy, or inability to tolerate 
appropriate doses of at least three statins. Prioritizing the use of combination 
therapy in these specific patient groups may help reduce cardiovascular outcomes 
and the impact of the associated physical and/or psychological disability.
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PRECISE-IVUS trial the Impact of Dual Lipid-Lowering Strategy With  
 Ezetimibe and Atorvastatin on Coronary Plaque  
 Regression in Patients With Percutaneous Coronary  
 Intervention: The Multicenter Randomized Controlled trial
PROVE-IT trial  Pravastatin or Atorvastatin Evaluation and Infection  
 Therapy trial
RCTs  randomized clinical trials
RMSE  root mean squared error
SC  subcutaneously
SD  standard deviation
SEARCH trial  in the Study of the Effectiveness of Additional Reductions  
 in Cholesterol and Homocysteine randomized trial
SEASE study  Simvastatin and Ezetimibe in Aortic Stenosis study
SHARP trial  the Study of Heart and Renal Protection (Simvastatin plus  
 ezetimibe) trial
19
© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms 
of the Creative Commons Attribution License (http://creativecommons.org/licenses/
by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, 
provided the original work is properly cited. 
Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic…
DOI: http://dx.doi.org/10.5772/intechopen.82520
SLC solute carrier
SPARCL trial in The Stroke Prevention by Aggressive Reduction of Cholesterol 
Levels trial
T2DM type 2 diabetes mellitus
TNF-α tumor necrosis factor-α
TNT trial treating to New Targets trial
UGT UDP-glucuronosyltransferase
VLDL very low-density lipoproteins
Author details
Marija Vavlukis1 and Ana Vavlukis2
1 University Clinic of Cardiology, Medical Faculty, Ss’ Cyril and Methodius 
University, Skopje, Republic of Macedonia
2 Faculty of Pharmacy, Ss’ Cyril and Methodius University, Skopje,  
Republic of Macedonia




[1] Ference BA, Ginsberg HN, Graham 
I, et al. Low-density lipoproteins 
cause atherosclerotic cardiovascular 
disease. 1. Evidence from genetic, 
epidemiologic, and clinical studies. A 
consensus statement from the European 
Atherosclerosis Society Consensus 
Panel. European Heart Journal. 
2017;38(32):2459-2472. DOI: 10.1093/
eurheartj/ehx144
[2] Nozue T. Lipid lowering therapy 
and circulating PCSK9 concentration. 
Journal of Atherosclerosis and 
Thrombosis. 2017;24(9):895-907. DOI: 
10.5551/jat.RV17012
[3] Catapano AL, Graham I, De 
Backer G, et al. The Task Force for the 
Management of Dyslipidaemias of 
the European Society of Cardiology 
(ESC) and European Atherosclerosis 
Society (EAS) developed with the 
special contribution of the European 
Assocciation for Cardiovascular 
Prevention & Rehabilitation (EACPR). 
2016 ESC/EAS Guidelines for the 
Management of Dyslipidaemias. 
European Heart Journal. 2016;37:2999-
3058. DOI: 10.1093/eurheartj/ehw272
[4] Robinson JG. Nonstatins and 
Proprotein Convertase Subtilisin/
Kexin Type 9 (PCSK9) inhibitors: Role 
in non-familial hypercholesterolemia. 
Progress in Cardiovascular Diseases. 
2016;59(2):165-171. DOI: 10.1016/j.
pcad.2016.07.009
[5] Ramkumar S, Raghunath A, 
Raghunath S. Statin therapy: Review of 
safety and potential side effects. Acta 
Cardiologica Sinica. 2016;32(6):631-639. 
DOI: 10.6515/ACS20160611A
[6] McFarland AJ, Anoopkumar-
Dukie S, Arora DS, et al. Molecular 
mechanisms underlying the effects 
of statins in the central nervous 
system. Harry GJ, ed. International 
Journal of Molecular Sciences. 
2014;15(11):20607-20637. DOI: 10.3390/
ijms151120607
[7] Gazzerro P, Proto MC, Gangemi G, 
et al. Pharmacological actions of statins: 
A critical appraisal in the management 
of cancer. Pharmacological Reviews. 
2012;64(1):102-146. DOI: 10.1124/
pr.111.004994
[8] Meor Anuar Shuhaili MFR, 
Samsudin IN, Stanslas J, et al. Effects 
of different types of statins on lipid 
profile: A perspective on Asians. 
International Journal of Endocrinology 
and Metabolism. 2017;15(2):e43319. 
DOI: 10.5812/ijem.43319
[9] Smith BA, Wright C, Davidson 
M. Role of Ezetimibe in lipid-
lowering and cardiovascular disease 
prevention. Current Atherosclerosis 
Reports. 2015;17:72. DOI: 10.1007/
s11883-015-0550-5
[10] Hammersley D, Signy M.  
Ezetimibe: An update on its clinical 
usefulness in specific patient groups. 
Therapeutic Advances in Chronic 
Disease. 2017;8(1):4-11. DOI: 
10.1177/2040622316672544
[11] Tie C, Gao K, Zhang N, et al. 
Ezetimibe attenuates atherosclerosis 
associated with lipid reduction and 
inflammation inhibition. PLoS One. 
2015;10(11):e0142430. DOI: 10.1371/
journal.pone.0142430
[12] Kim H, Choi HY, Kim YH, et al. 
Pharmacokinetic interactions and 
tolerability of rosuvastatin and 
ezetimibe: An open-label, randomized, 
multiple-dose, crossover study in 
healthy male volunteers. Drug Design, 
Development and Therapy. 2018;12:815-
821. DOI: 10.2147/DDDT.S158408
[13] Nabil GS. Proprotein Convertase 
Subtilisin Kexin 9 (PCSK9) 
inhibitors in the treatment of 
21
Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic…
DOI: http://dx.doi.org/10.5772/intechopen.82520
hypercholesterolemia and other 
pathologies. Current Pharmaceutical 
Design. 2013;19:3161-3172. DOI: 
10.2174/13816128113199990313
[14] Page MM, Watts GF. PCSK9 
inhibitors—Mechanisms of action. 
Australian Prescriber. 2016;39(5):164-
167. DOI: 10.18773/austprescr.2016.060
[15] Giugliano RP, Sabatine MS. Are 
PCSK9 inhibitors the next breakthrough 
in the cardiovascular field? Journal of 
the American College of Cardiology. 
2015;65(24):2638-2651. DOI: 10.1016/j.
jacc.2015.05.001
[16] Hess PL, Kennedy K, Cowherd M, 
et al. Implications of the FDA approval 
of PCSK9 inhibitors and FOURIER 
results for contemporary cardiovascular 
practice: An NCDR research to practice 
(R2P) project. American Heart Journal. 
2018;195:151-152. DOI: 10.1016/j.
ahj.2017.09.004
[17] Fala L. Repatha (Evolocumab): 
Second PCSK9 inhibitor approved 
by the FDA for patients with familial 
hypercholesterolemia. American Health 
& Drug Benefits. 2016;9 
(Spec Feature):136-139
[18] Manniello M, Pisano M. Alirocumab 
(Praluent): First in the new class of 
PCSK9 inhibitors. Pharmacy and 
Therapeutics. 2016;41(1):28-53
[19] Carroll MD, Kit BK, Lacher DA, 
Shero ST, Mussolino ME. Trends 
in lipids and lipoproteins in US 
adults, 1988-2010. Journal of the 
American Medical Association. 
2012;308:1545-1554
[20] Stone NJ, Robinson JG, Lichtenstein 
AH, et al. 2013 ACC/AHA guideline on 
the treatment of blood cholesterol to 
reduce atherosclerotic cardiovascular 
risk in adults: A report of the American 
College of Cardiology/American Heart 
Association Task Force on Practice 
Guidelines. Circulation. 2014;129 
(suppl 2):S1-S45
[21] Soran H, Schofield JD, 
Durrington PN. Cholesterol, not just 
cardiovascular risk, is important in 
deciding who should receive statin 
treatment. European Heart Journal. 
2015;36:2975-2983
[22] Cholesterol Treatment Trialists’ 
(CTT) Collaboration. Efficacy and 
safety of more intensive lowering 
of LDL cholesterol: A meta-analysis 
of data from 170 000 participants 
in 26 randomised trials. Lancet. 
2010;376:1670-1681
[23] Cholesterol Treatment Trialists’ 
(CTT) Collaborators. The effects of 
lowering LDL cholesterol with statin 
therapy in people at low risk of vascular 
disease: Meta-analysis of individual 
data from 27 randomised trials. Lancet. 
2012;380:581-590
[24] Soran H, Dent R, Durrington 
P. Evidence-based goals in LDL-C 
reduction. Clinical Research in 
Cardiology. 2017;106:237-248. DOI: 
10.1007/s00392-016-1069-7
[25] Collins R, Reith C, Emberson J, et al. 
Interpretation of the evidence for the 
efficacy and safety of statin therapy. 
Lancet. 2016;388:2532-2561. DOI: 
10.1016/ S0140-6736(16)31357-5
[26] Jellinger PS, Handelsman Y, 
Rosenblit PD, et al. AACE 2017 
Guidelines, American Association of 
Clinical Endocrinologists and American 
College of Endocrinology Guidelines 
for Management of Dyslipidemia and 
Prevention of Cardiovascular Disease. 
Endocrine Practice. 2017;23(Suppl 2):1-63
[27] LaRosa JC, Grundy SM, Waters 
DD, et al. Intensive lipid lowering with 
atorvastatin in patients with stable 
coronary disease. The New England 
Journal of Medicine. 2005;352:1425-
1435. DOI: 10.1056/NEJMoa050461
[28] Pedersen TR, Faergeman O,  
Kastelein JJ, et al. High-dose 
Lipid Peroxidation Research
22
atorvastatin vs usual-dose simvastatin 
for secondary prevention after 
myocardial infarction the IDEAL study: 
A randomized controlled trial. Journal 
of the American Medical Association. 
2005;294(19):2437-2445. DOI: 10.1001/
jama.294.19.2437
[29] Cannon CP, Braunwald E, McCabe 
CH, et al. Intensive versus moderate 
lipid lowering with statins after acute 
coronary syndromes. The New England 
Journal of Medicine. 2004;350:1495-
1504. DOI: 10.1056/NEJMoa040583
[30] Baer J. AACE and EAS lipid 
guidelines. Expert analysis. AACE 
and EAS lipid guidelines—American 




[31] Robinson JG, Rogers WJ, 
Nedergaard BS, et al. Rationale and 
design of LAPLACE-2: A phase 3, 
randomized, double-blind, placebo- and 
Ezetimibe-controlled trial evaluating 
the efficacy and safety of Evolocumab 
in subjects with hypercholesterolemia 
on background statin therapy. Clinical 
Cardiology. 2014;37(4):195-203. DOI: 
10.1002/clc.22252
[32] Ray KK, Ginsberg HN, Davidson 
MH, et al. Reductions in atherogenic 
lipids and major cardiovascular 
events: A pooled analysis of 
10 ODYSSEY trials comparing 
alirocumab with control. Circulation. 
2016;134(24):1931-1943. DOI: 10.1161/
CIRCULATIONAHA.116.024604
[33] Sabatine MS, Giugliano RP, 
Keech AC, et al. Evolocumab and 
clinical outcomes in patients with 
cardiovascular disease. The New 
England Journal of Medicine. 
2017;376(1713):1722. DOI: 10.1056/
NEJMoa1615664
[34] Cannon CP, Blazing MA, Giugliano 
RP, et al. Ezetimibe added to statin 
therapy after acute coronary syndromes. 
The New England Journal of Medicine. 
2015;372(2387):2397. DOI: 10.1056/
NEJMoa1410489
[35] Lloyd-Jones D, Morris P, Ballantyne 
C, et al. 2016 ACC expert consensus 
decision pathway on the role of non-statin 
therapies for LDL-cholesterol lowering 
in the management of atherosclerotic 
cardiovascular disease risk: A report 
of the American College of Cardiology 
Task Force on Clinical Expert Consensus 
Documents. Journal of the American 
College of Cardiology. 2016;68:92-125. 
DOI: 10.1016/j.jacc.2016.03.519
[36] Descamps O, Tomassini JE, Lin J, 
et al. Variability of the LDL-C lowering 
response to ezetimibe and ezetimibe + 




[37] Toth PP, Foody JM, Tomassini JE, 
et al. Therapeutic practice patterns 
related to statin potency and ezetimibe/
simvastatin combination therapies in 
lowering LDL-C in patients with high-
risk cardiovascular disease. Journal of 
Clinical Lipidology. 2014;8(1):107-116. 
DOI: 10.1016/j.jacl.2013.09.009
[38] Bohula E, Giugliano R, Cannon 
C, et al. Achievement of dual low-
density lipoprotein cholesterol and 
high-sensitivity C-reactive protein 
targets more frequent with the 
addition of ezetimibe to simvastatin 




[39] Uemura Y, Watarai M, Ishii H, et al. 
Atorvastatin 10 mg plus ezetimibe 
10 mg compared with atorvastatin 
20 mg: Impact on the lipid profile in 
Japanese patients with abnormal glucose 
tolerance and coronary artery disease. 
Journal of Cardiology. 2012;59(1):50-56. 
DOI: 10.1016/j.jjcc.2011.09.001
23
Statins Alone or in Combination with Ezetimibe or PCSK9 Inhibitors in Atherosclerotic…
DOI: http://dx.doi.org/10.5772/intechopen.82520
[40] Tobaru T, Seki A, Asano R, et al. 
Lipid-lowering and anti-inflammatory 
effect of ezetimibe in hyperlipidemic 
patients with coronary artery disease. 
Heart and Vessels. 2013;28(1):39-45. 
DOI: 10.1007/s00380-012-0243-8
[41] Tsujita K, Sugiyama S, Sumida 
H, et al. Impact of dual lipid-
lowering strategy with Ezetimibe 
and atorvastatin on coronary plaque 
regression in patients with percutaneous 
coronary intervention: The multicenter 
randomized controlled PRECISE-IVUS 
trial. Journal of the American College of 
Cardiology. 2015;66(5):495-507. DOI: 
10.1016/j.jacc.2015.05.065
[42] Mancini J, Hegele R, Leiter L.  
Dyslipidemia. Canadian Diabetes 
Association clinical practice guidelines 
expert committee. Canadian Journal of 
Diabetes. 2013;37(Suppl 1):S110-S116. 
DOI: 10.1016/j.jcjd.2013.01.032
[43] Lovadi E, Csécsei P, Lovig C, 
et al. Lipids and cerebrovascular 
disease—New therapeutic options 
in lowering LDL-cholesterol. Orvosi 
Hetilap. 2016;157(52):2059-2065. DOI: 
10.1556/650.2016.30643
[44] Lepor NE, Kereiakes DJ. The PCSK9 
inhibitors: A novel therapeutic target 
enters clinical practice. American Health 
& Drug Benefits. 2015;8(9):483-489
[45] Landmesser U, Chapman MJ, Stock 
JK, et al. 2017 update of ESC/EAS task 
force on practical clinical guidance 
for proprotein convertase subtilisin/
kexin type 9 inhibition in patients with 
atherosclerotic cardiovascular disease 
or in familial hypercholesterolaemia. 
European Heart Journal. 2017;0:1-13
[46] Sabatine MS, Giugliano RP, Keech 
AC, et al. FOURIER steering committee 
and investigators. Evolocumab 
and clinical outcomes in patients 
with cardiovascular disease. The 
New England Journal of Medicine. 
2017;376:1713-1722
[47] Nissen SE, Stroes E, Dent-Acosta 
R, et al. Efficacy and tolerability 
of Evolocumab vs Ezetimibe in 
patients with muscle-related statin 
IntoleranceThe GAUSS-3 randomized 
clinical trial. Journal of the American 
Medical Association. 2016;315(15):1580-
1590. DOI: 10.1001/jama.2016.3608
[48] Macedo AF, Taylor FC, Casas JP, 
et al. Unintended eff ects of statins 
from observational studies in the 
general population: Systematic review 
and meta-analysis. BMC Medicine. 
2014;12:51
[49] SEARCH Collaborative Group. 
Intensive lowering of LDL cholesterol 
with 80 mg versus 20 mg simvastatin 
daily in 12 064 survivors of myocardial 
infarction: A double-blind randomised 
trial. Lancet. 2010;376:1658-1669
[50] Ridker PM. The JUPITER 
Trial-results, controversies, and 
implications for prevention. Circulation: 
Cardiovascular Quality and Outcomes. 
2009;2:279-285
[51] Huisa BN, Stemer AB, Zivin JA.  
Atorvastatin in stroke: A review 
of SPARCL and subgroup analysis. 
Vascular Health and Risk Management. 
2010;6:229-236
[52] Wu H, Shang H, Wu J. Effect of 
ezetimibe on glycemic control: A 
systematic review and meta-analysis 
of randomized controlled trials. 
Endocrine. 2018;60(2):229-239. DOI: 
10.1007/s12020-018-1541-4
[53] Saxon DR, Eckel RH. Statin 
intolerance: A literature review and 
management strategies. Progress 
in Cardiovascular Diseases. 
2016;59(2):153-164. DOI: 10.1016/j.
pcad.2016.07.009
[54] Olsson AG, Angelin B, Assmann 
G, et al. Can LDL cholesterol be too 
low? Possible risks of extremely low 




[55] Khan SU, Talluri S, Riaz H, et al. 
A Bayesian network meta-analysis 
of PCSK9 inhibitors, statins and 
ezetimibe with or without statins 
for cardiovascular outcomes. 
European Journal of Preventive 
Cardiology. 2018;25(8):844-853. DOI: 
10.1177/2047487318766612
